<DOC>
	<DOCNO>NCT01650597</DOCNO>
	<brief_summary>The purpose study investigate safety , tolerability pharmacokinetics single ascending dos well repeat dos JNJ-42165279 healthy male participant .</brief_summary>
	<brief_title>A Single Ascending Dose Study Investigate Safety , Tolerability , Pharmacokinetics JNJ-42165279 Healthy Male Participants</brief_title>
	<detailed_description>This single-site , randomize ( participant assign treatment chance ) , double-blind study ( neither physician participant know whether participant receive active treatment placebo ) . Placebo inactive substance compare drug test whether drug real effect . This study consist two part ( part 1 , single dose part 2 , multiple dosing ) . Part 1 : An alternate panel design use , whereby first panel 9 participant receive first , third , fifth administer dos , second panel 9 participant receive second , fourth , sixth administer doses.Up 2 additional dosings ( 1 per panel ) may evaluate understand study drug . For dose administration , 6 participant assign active treatment 3 placebo . Each participant receive JNJ-42165279 2 occasion placebo first 3 dosings . The planned dos JNJ-42165279 range 2.5 500 mg . The sponsor investigator review blind data associate dose prior administration next dose . Participants check study center morning prior dosing ( Day -1 ) remain center discharge 72 hour dose ( Day 4 ) . Participants dose approximately every 4 week . Part 2 : A separate cohort 9 healthy male volunteer receive repeat daily dose 100 mg JNJ-42165279 placebo ( 6 participant receive JNJ-42165279 3 participant receive placebo ) 6 consecutive day . Participants check study center morning prior first dose ( Day -1 ) remain center discharge 72 hour receive last dose Day 6 . Participants Part 1 2 return follow-up visit 7 14 day final discharge study center .</detailed_description>
	<criteria>Has body mass index 18 30 kg/m2 body weight less 50 kg . Must adhere require contraception ( subject partner , applicable ) study 3 month study Must agree donate sperm study 3 month receive last dose study drug Has history current clinically significant medical illness include cardiac arrhythmia cardiac disease , hematologic disease , coagulation disorder ( include abnormal bleeding blood dyscrasia ) , lipid abnormality , significant pulmonary disease , include bronchospastic respiratory disease , diabetes mellitus , renal hepatic insufficiency , thyroid disease , neurologic psychiatric disease , infection , recent surgery trauma . Has history malignancy within 5 year screen ( exception squamous basal cell carcinoma skin , malignancy opinion investigator , concurrence sponsor 's medical monitor , consider cure minimal risk recurrence ) Has clinically significant abnormal value hematology , clinical chemistry , coagulation , urinalysis screen first admission study center . Has clinically significant abnormal physical examination , neurological examination , vital sign , 12lead electrocardiogram ( ECG ) screen first admission study center . Subjects QTcF interval &gt; 450 msec QRS interval â‰¥110 msec exclude . Has use prescription nonprescription medication herbal supplement , except paracetamol , within 14 day first dose study drug . Paracetamol allow within 1 day ( Day 1 ) first dose study drug . Has know allergy , hypersensitivity , intolerance hypromellose ( excipient JNJ42165279 ) Has Known allergy heparin history heparin induce thrombocytopenia Has positive test human immunodeficiency virus ( HIV ) 1 2 antibody , hepatitis B core antibody ( HBcAB ) , hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody ( HCV ) Has history significant drug alcohol abuse within past 5 year , positive drug screen Smoking use nicotinecontaining substance within past 2 month Blood donation blood loss within past 3 month Recent use investigational drug device</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Healthy volunteer</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Free fatty amide</keyword>
</DOC>